Physician
Medical Group of Alaska
Medical Group of Alaska was paid $6.97M by Medicaid between Jan 2018 and Dec 2024, across 46 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 65% of everything it billed.
33Billing provider infoMEDICAL GROUP OF ALASKA
WASILLA, AK 99654
WASILLA, AK 99654
33aNPI1174882971assigned 05/14/2012
33bProvider typePain Medicine Physician
28Total paid$6.97M
24GClaims108,105
24DCodes billed46
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,057 | $1.09M | |
| 2019 | 16,749 | $1.13M | |
| 2020 | 12,748 | $890K | |
| 2021 | 14,643 | $1.03M | |
| 2022 | 16,176 | $1.03M | |
| 2023 | 17,693 | $1.01M | |
| 2024incomplete | 13,039 | $791K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 65% | 52,851 | 38,663 | $4.50M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 20% | 20,918 | 15,542 | $1.37M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12% | 20,060 | 14,657 | $830K |
| 62323 | <1% | 294 | 231 | $51K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 245 | 201 | $38K |
| 20611 | <1% | 542 | 382 | $38K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,184 | 1,088 | $25K |
| 64493 | <1% | 71 | 53 | $11K | |
| 20553 | <1% | 216 | 154 | $11K | |
| 99152 | <1% | 289 | 192 | $10K | |
| 64635 | <1% | 21 | 15 | $8K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 655 | 525 | $7K |
34 more codes
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 57 | $7K |
| 81025 | <1% | 878 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 195 | $5K |
| 27096 | <1% | 34 | $5K | |
| 76942 | <1% | 87 | $5K | |
| 62369 | <1% | 112 | $4K | |
| 64636 | <1% | 25 | $4K | |
| 64483 | <1% | 19 | $4K | |
| 64494 | <1% | 42 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,359 | $3K |
| 96132 | <1% | 149 | $3K | |
| 96130 | <1% | 149 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 479 | $2K |
| 76882 | <1% | 30 | $2K | |
| 20610 | <1% | 50 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 271 | $1K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,021 | $1K |
| 99153 | Mod sedat endo service >5yrs | <1% | 88 | $812.63 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 265 | $721.53 |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 149 | $679.63 |
| 64450 | <1% | 14 | $661.38 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 17 | $580.17 |
| 96138 | <1% | 149 | $547.50 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 199 | $437.41 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 789 | $281.59 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 220 | $111.25 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 194 | $64.68 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 690 | $16.31 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,101 | $3.97 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 143 | $0.46 |
| 36415 | Collection of venous blood by venipuncture | 0% | 84 | $0.00 |
| 99156 | 0% | 29 | $0.00 | |
| A4550 | Surgical trays | 0% | 110 | $0.00 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 561 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENRY-MUSA, CHRISTINE (CEO)
Parent organizationLYNX MEDICAL SERVICES ORGANIZATION
| Provider | Location | Paid |
|---|---|---|
| Medical Group of Alaska | Wasilla, AK | $1.36M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.